• Users Online: 98
  • Print this page
  • Email this page
Year : 2020  |  Volume : 9  |  Issue : 1  |  Page : 37-41

Immune dysregulation in COVID-19 and its therapeutic implications

Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
N Wig
Professor and Head, Department of Medicine, All India Institute of Medical Sciences, New Delhi 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCSR.JCSR_40_20

Rights and Permissions

Many countries in the world are affected by severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) disease-2019 (COVID-19) pandemic. Approximately 80% of the cases are mild symptomatic, 15% are severe and approximately 5% are critically ill. The mortality among severe and critically ill patients ranges from 17% to 78%. Elderly and patients with comorbidities have higher chances of progression to severe disease and subsequent mortality. There are no proven antiviral agents available for the management of COVID-19. Besides the viral cytopathic effects, dysregulation in immunity also contributes substantially to the pathogenesis. Treatment with immunomodulatory agents such as interleukin-6 blockers, glucocorticoids and mesenchymal stem cell therapy has been observed to be potentially beneficial. In this review, the immune response in SARS-CoV-2, the mechanism of immune dysregulation as well as potential therapeutic targets for immunomodulatory therapies are discussed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal